Publications
Detailed Information
Optimal use of antithrombotic agents in ischemic stroke with atrial fibrillation and large artery atherosclerosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Tae Jung | - |
dc.contributor.author | Lee, Ji Sung | - |
dc.contributor.author | Yoon, Jae Sun | - |
dc.contributor.author | Oh, Mi Sun | - |
dc.contributor.author | Kim, Ji-Woo | - |
dc.contributor.author | Park, Soo-Hyun | - |
dc.contributor.author | Jung, Keun-Hwa | - |
dc.contributor.author | Kim, Hyun Young | - |
dc.contributor.author | Kwon, Jee-Hyun | - |
dc.contributor.author | Choi, Hye-Yeon | - |
dc.contributor.author | Kim, Hahn Young | - |
dc.contributor.author | Eah, Kyung Yoon | - |
dc.contributor.author | Han, Sang Won | - |
dc.contributor.author | Oh, Hyung-Geun | - |
dc.contributor.author | Kim, Young-Jae | - |
dc.contributor.author | Shin, Byoung-Soo | - |
dc.contributor.author | Kim, Chang Hun | - |
dc.contributor.author | Kim, Chi Kyung | - |
dc.contributor.author | Park, Jong-Moo | - |
dc.contributor.author | Lee, Kyung Bok | - |
dc.contributor.author | Park, Tai Hwan | - |
dc.contributor.author | Lee, Jun | - |
dc.contributor.author | Park, Man-Seok | - |
dc.contributor.author | Choi, Jay Chol | - |
dc.contributor.author | Kim, Chulho | - |
dc.contributor.author | Shin, Dong-Ick | - |
dc.contributor.author | Lee, Soo Joo | - |
dc.contributor.author | Kim, Dong-Eog | - |
dc.contributor.author | Cha, Jae-Kwan | - |
dc.contributor.author | Kim, Eung-Gyu | - |
dc.contributor.author | Yu, Kyung-Ho | - |
dc.contributor.author | Hong, Keun-Sik | - |
dc.contributor.author | Lee, Young-Seok | - |
dc.contributor.author | Lee, Ju-Hun | - |
dc.contributor.author | Sohn, Sung Il | - |
dc.contributor.author | Bae, Hee-Joon | - |
dc.contributor.author | Lee, Young-Bae | - |
dc.contributor.author | Lee, Jun Hong | - |
dc.contributor.author | Rha, Joung-Ho | - |
dc.contributor.author | Lee, Byung-Chul | - |
dc.contributor.author | Chang, Dae-Il | - |
dc.contributor.author | Ko, Sang-Bae | - |
dc.contributor.author | Yoon, Byung-Woo | - |
dc.date.accessioned | 2024-08-08T01:20:39Z | - |
dc.date.available | 2024-08-08T01:20:39Z | - |
dc.date.created | 2023-04-27 | - |
dc.date.created | 2023-04-27 | - |
dc.date.issued | 2023-08 | - |
dc.identifier.citation | International Journal of Stroke, Vol.18 No.7, pp.1-820 | - |
dc.identifier.issn | 1747-4930 | - |
dc.identifier.uri | https://hdl.handle.net/10371/205229 | - |
dc.description.abstract | Background: Optimal antithrombotic regimens to prevent recurrent stroke in patients with ischemic stroke due to atrial fibrillation (AF) and atherosclerotic large-vessel stenosis remain unknown. Aims: This study aimed to evaluate the effect of multiple antithrombotic therapies on outcomes at 1 year after ischemic stroke due to two or more causes. Methods: We identified 862 patients with ischemic stroke due to AF and large artery atherosclerosis from the linked data. These patients were categorized into three groups according to antithrombotic therapies at discharge: (1) antiplatelets, (2) oral anticoagulants (OAC), and (3) antiplatelets plus OAC. The study outcomes were recurrent ischemic stroke, composite outcomes for cardiovascular events, and major bleeding after 1 year. Inverse probability of treatment weighting (IPTW) was used to balance the three groups using propensity scores. Results: Among 862 patients, 169 (19.6%) were treated with antiplatelets, 405 (47.0%) were treated with OAC, and 288 (33.4%) were treated with antiplatelets and OAC. After applying IPTW, only OAC had a significant beneficial effect on the 1-year composite outcome (hazard ratio (HR): 0.37, 95% confidence interval (CI): 0.23-0.60, p < 0.001) and death (HR: 0.35, 95% CI: (0.19-0.63), p < 0.001). The combination of antiplatelet agents and OAC group had an increased risk of major bleeding complications (HR: 5.27, 95% CI: (1.31-21.16), p = 0.019). However, there was no significant difference in 1-year recurrent stroke events among the three groups. Conclusion: This study demonstrated that OAC monotherapy was associated with lower risks of composite outcome and death in patients at 1 year after ischemic stroke due to AF and atherosclerotic stenosis. In addition, the combination of an antiplatelet and OAC had a high risk of major bleeding. | - |
dc.language | 영어 | - |
dc.publisher | Blackwell | - |
dc.title | Optimal use of antithrombotic agents in ischemic stroke with atrial fibrillation and large artery atherosclerosis | - |
dc.type | Article | - |
dc.identifier.doi | 10.1177/17474930231158211 | - |
dc.citation.journaltitle | International Journal of Stroke | - |
dc.identifier.wosid | 000941198700001 | - |
dc.identifier.scopusid | 2-s2.0-85150497790 | - |
dc.citation.endpage | 820 | - |
dc.citation.number | 7 | - |
dc.citation.startpage | 1 | - |
dc.citation.volume | 18 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Bae, Hee-Joon | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | PERCUTANEOUS CORONARY INTERVENTION | - |
dc.subject.keywordPlus | DIRECT ORAL ANTICOAGULANTS | - |
dc.subject.keywordPlus | ANTIPLATELET THERAPY | - |
dc.subject.keywordPlus | INVERSE PROBABILITY | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | ASPIRIN | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | CLOPIDOGREL | - |
dc.subject.keywordPlus | SUBTYPE | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordAuthor | Antithrombotic | - |
dc.subject.keywordAuthor | ischemic stroke | - |
dc.subject.keywordAuthor | secondary prevention | - |
dc.subject.keywordAuthor | atrial fibrillation | - |
dc.subject.keywordAuthor | large artery atherosclerosis | - |
dc.subject.keywordAuthor | treatment | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.